title: Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection.
abstract: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract illnesses in infants worldwide. Both RSV-G and RSV-F glycoproteins play pathogenic roles during infection with RSV. The objective of this study was to compare the effects of anti-RSV-G and anti-RSV-F monoclonal antibodies (mAbs) on airway hyperresponsiveness (AHR) and inflammation after primary or secondary RSV infection in mice. In the primary infection model, mice were infected with RSV at 6 weeks of age. Anti-RSV-G or anti-RSV-F mAbs were administered 24 hours before infection or Day +2 postinfection. In a secondary infection model, mice were infected (primary) with RSV at 1 week (neonate) and reinfected (secondary) 5 weeks later. Anti-RSV-G and anti-RSV-F mAbs were administered 24 hours before the primary infection. Both mAbs had comparable effects in preventing airway responses after primary RSV infection. When given 2 days after infection, anti-RSV-G-treated mice showed significantly decreased AHR and airway inflammation, which persisted in anti-RSV-F-treated mice. In the reinfection model, anti-RSV-G but not anti-RSV-F administered during primary RSV infection in neonates resulted in decreased AHR, eosinophilia, and IL-13 but increased levels of IFN-γ in bronchoalveolar lavage on reinfection. These results support the use of anti-RSV-G in the prevention and treatment of RSV-induced disease.
authors: Division of Cell Biology, Department of Pediatrics, National Jewish Health, Denver, Colorado.
authors: Junyan
authors: J
authors: Han
authors: Katsuyuki
authors: K
authors: Takeda
authors: Meiqin
authors: M
authors: Wang
authors: Wanjiang
authors: W
authors: Zeng
authors: Yi
authors: Y
authors: Jia
authors: Yoshiki
authors: Y
authors: Shiraishi
authors: Masakazu
authors: M
authors: Okamoto
authors: Azzeddine
authors: A
authors: Dakhama
authors: Erwin W
authors: EW
authors: Gelfand
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000276:immunology / Q000627:therapeutic use; D001990:Bronchiolitis, Viral / Q000209:etiology / Q000517:prevention & control*; D016207:Cytokines / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D007249:Inflammation / Q000209:etiology / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D012130:Respiratory Hypersensitivity / Q000209:etiology / Q000517:prevention & control*; D018357:Respiratory Syncytial Virus Infections / Q000150:complications / Q000276:immunology / Q000517:prevention & control*; D012136:Respiratory Syncytial Viruses / Q000276:immunology / Q000472:pathogenicity; D014760:Viral Fusion Proteins / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D016207:Cytokines; C526850:F protein, human respiratory syncytial virus; C502275:G glycoprotein, Respiratory syncytial virus; D014760:Viral Fusion Proteins
keywords: airway; anti–respiratory syncytial virus–F; anti–respiratory syncytial virus–G; inflammation; respiratory syncytial virus